Suzhou Fushilai Pharmaceutical Co., Ltd. Class A

Suzhou Fushilai Pharmaceutical Co., Ltd. Class A

SSZSE:301258
22.50
CNY
-0.12
(-0.53%)
-0.53EPS
2.51BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Suzhou Fushilai Pharmaceutical Co., Ltd. Class A carries a market capitalization of 2.51B, placing it among publicly traded companies globally. Its enterprise value stands at 1.39B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.51B
Enterprise Value1.39B

Share Statistics

As of September 30, 2026, Suzhou Fushilai Pharmaceutical Co., Ltd. Class A has 91.67M shares outstanding.

Shares Outstanding91.67M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 6.47, and the price-to-book ratio stands at 1.39.

PS Ratio6.47
PB Ratio1.39
P/TBV Ratio1.44

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 3.71 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.39B versus a market cap of 2.51B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales3.71

Financial Position

As of September 30, 2026, Suzhou Fushilai Pharmaceutical Co., Ltd. Class A maintains a current ratio of 9.70, meaning it holds 9.7x the short-term assets needed to cover near-term liabilities.

Current Ratio9.70
Quick Ratio7.84
Interest Coverage-1,398.82

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Suzhou Fushilai Pharmaceutical Co., Ltd. Class A posted a negative return on equity (ROE) of -2.53, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -2.28, reflecting losses generated across the asset base. The company generates approximately 694,798.57 in revenue per employee across its workforce of 540.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.44 indicates how many times Suzhou Fushilai Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-2.53
Return on Assets (ROA)-2.28
Revenue Per Employee694,798.57
Employee Count540.00
Inventory Turnover2.44

Taxes

CNY

Over the twelve months ended September 30, 2026, Suzhou Fushilai Pharmaceutical Co., Ltd. Class A recorded an income tax benefit of -8.03M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -55.22M and -47.19M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-8.03M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Suzhou Fushilai Pharmaceutical Co., Ltd. Class A's stock has declined approximately 37.67% over the past 52 weeks. The 50-day moving average sits at 24.91, while the 200-day moving average is 28.08.

52-Week Price Change-37.67%
50-Day Moving Average24.91
200-Day Moving Average28.08

Income Statement

CNY

Over the twelve months ended September 30, 2026, Suzhou Fushilai Pharmaceutical Co., Ltd. Class A generated 375.19M in revenue and converted that into -47.19M in net income, yielding earnings per share of -0.53. EBITDA reached -52.29M, while operating income came in at -39.80M.

Revenue375.19M
Gross Profit43.50M
Operating Income-39.80M
Pretax Income-55.22M
Net Income-47.19M
EBITDA-52.29M
EBIT-52.29M
Earnings Per Share (EPS)-0.53

Balance Sheet

CNY

These figures are as of September 30, 2026. Total book value stands at 1.81B, with working capital of 1.24B providing operational flexibility.

Cash & Cash Equivalents1.12B
Net Debt-495.14M
Equity (Book Value)1.81B
Book Value Per Share19.71
Working Capital1.24B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-113.21M

Margins

Over the twelve months ended September 30, 2026, Suzhou Fushilai Pharmaceutical Co., Ltd. Class A posted a gross margin of 11.60, reflecting its pricing power and cost economics. The operating margin of -10.61 and net profit margin of -12.58 provide insight into operational efficiency.

Gross Margin11.60
Operating Margin-10.61
Pretax Margin-14.72
Profit Margin-12.58
EBITDA Margin-13.94

Dividends & Yields

Over the twelve months ended September 30, 2026, Suzhou Fushilai Pharmaceutical Co., Ltd. Class A paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 2.31, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Suzhou Fushilai Pharmaceutical Co., Ltd. Class A shareholders.

Shareholder Yield2.31

Scores

As of September 30, 2026, Suzhou Fushilai Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 9.21, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score9.21